Form 15-12G - Securities registration termination [Section 12(g)]
June 03 2024 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-39971
LANDOS BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
P.O. Box
11239
Blacksburg, VA 24062
(540) 218-2232
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Common Stock, $0.01 par value per share
(Title of each class of securities covered by this Form)
None
(Titles of all
other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an
X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
Rule 12g-4(a)(1) |
|
☒ |
Rule 12g-4(a)(2) |
|
☐ |
Rule 12h-3(b)(1)(i) |
|
☒ |
Rule 12h-3(b)(1)(ii) |
|
☐ |
Rule 15d-6 |
|
☐ |
Rule 15d-22(b) |
|
☐ |
Approximate number of holders of record as of the certification or notice date: 1.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, Landos Biopharma, Inc. has caused this certification/notice
to be signed on its behalf by the undersigned duly authorized person.
|
|
|
|
|
|
|
Date: June 3, 2024 |
|
|
|
By: |
|
/s/ Fabio Cataldi |
|
|
|
|
Name: |
|
Fabio Cataldi |
|
|
|
|
Title: |
|
Authorized Officer |
Landos Biopharma (NASDAQ:LABP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Landos Biopharma (NASDAQ:LABP)
Historical Stock Chart
From Aug 2023 to Aug 2024